参考文献/References:
[1] Ommen SR,Mital S,Burke MA,et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy:executive summary:a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines[J]. Circulation,2020 ,142(25):e533-e557.
[2] Zou Y,Song L,Wang Z,et al. Prevalence of idiopathic hypertrophic cardiomyopathy in China:a population-based echocardiographic analysis of 8080 adults[J]. Am J Med,2004,116(1):14-18
[3] Ho CY,Mealiffe ME,Bach RG,et al. Evaluation of mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy[J]. J Am Coll Cardiol,2020,75(21):2649-2660.
[4] Antal A,Boyac?o?lu K,Akbulut M,et al. Surgical management of hypertrophic
obstructive cardiomyopathy[J]. Gen Thorac Cardiovasc Surg,2020,68(9):962-968.
[5] Alashi A,Smedira NG,Hodges K,et al. Outcomes in guideline-based class I indication versus earlier referral for surgical myectomy in hypertrophic obstructive cardiomyopathy[J]. J Am Heart Assoc,2021,10(1):e016210.
[6] Ji Q,Wang YL,Yang Y,et al. Mini-invasive surgical instruments in transaortic myectomy for hypertrophic obstructive cardiomyopathy:a single-center experience with 168 cases[J]. J Cardiothorac Surg,2021,16(1):25.
[7] Veselka J,Faber L,Liebregts M,et al. Alcohol dose in septal ablation for hypertrophic obstructive cardiomyopathy [J]. Int J Cardiol,2021,333:127-132.
[8] Batzner A,Pfeiffer B,Neugebauer A,et al. Survival after alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy[J]. J Am Coll Cardiol,2018,72(24):3087-3094.
[9] Byty?i I,Nistri S,M?rner S,et al. Alcohol septal ablation versus septal myectomy treatment of obstructive hypertrophic cardiomyopathy:a systematic review and meta-analysis[J]. J Clin Med,2020 ,9(10):3062.
[10] Sathyamurthy I,Nayak R,Oomman A,et al. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy—8 years follow up[J]. Indian Heart J,2014,66(1):57-63.
[11] Veselka J,Faber L,Liebregts M,et al. Alcohol dose in septal ablation for hypertrophic obstructive cardiomyopathy [J]. Int J Cardiol,2021,333:127-132.
[12] Oto A,Aytemir K,Okutucu S,et al. Cyanoacrylate for septal ablation in hypertrophic cardiomyopathy[J]. J Interv Cardiol,2011,24(1):77-84.
[13] Durand E,Mousseaux E,Coste P,et al. Non-surgical septal myocardial reduction by coil embolization for hypertrophic obstructive cardiomyopathy:early and 6 months follow-up[J]. Eur Heart J,2008,29(3):348-355.
[14] Liu F,Fu J,Hsi D,et al. Percutaneous intramyocardial septal radiofrequency ablation for interventricular septal reduction:an ovine model with 1-year outcomes[J]. Cardiology,2020,145(1):53-62.
[15] Liu L,Li J,Zuo L,et al. Percutaneous intramyocardial septal radiofrequency ablation for hypertrophic obstructive cardiomyopathy[J]. J Am Coll Cardiol,2018,72(16):1898-1909.
[16] Cooper RM,Shahzad A,Hasleton J,et al. Radiofrequency ablation of the interventricular septum to treat outflow tract gradients in hypertrophic obstructive cardiomyopathy:a novel use of CARTOSound? technology to guide ablation[J]. Europace,2016,18(1):113- 120.
[17] Creta A,Elliott P,Earley MJ,et al. Catheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy:a European observational multicenter study[J]. Europace,2021,23(9):1409-1417.
[18] Loo BW Jr,Soltys SG,Wang L,et al. Stereotactic ablative radiotherapy for the treatment of refractory cardiac ventricular arrhythmia[J]. Circ Arrhythm Electrophysiol,2015,8(3):748-750.
[19] Cuculich PS,Schill MR,Kashani R,et al. Noninvasive cardiac radiation for ablation of ventricular tachycardia[J]. N Engl J Med,2017,377(24):2325-2336.
相似文献/References:
[1]冯坤,刘春霞,熊峰,等.超声心动图在肥厚型心肌病诊治中的应用进展[J].心血管病学进展,2016,(4):409.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.021]
FENG Kun,LIU Chunxia,XIONG Feng,et al.Progress in Application of Echocardiography in
Diagnosis and Treatment of Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2016,(1):409.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.021]
[2]黄淮滨 刘甲兴.肥厚型心肌病治疗新靶点——钙脱敏治疗[J].心血管病学进展,2019,(7):1047.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.021]
HUANG HuaibinLIU Jiaxing.A Novel Target for Therapy in Hypertrophic Cardiomyopathy: Ca2+ desensitizer[J].Advances in Cardiovascular Diseases,2019,(1):1047.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.021]
[3]马秀英 贾锋鹏.肥厚型心肌病并发心房颤动的危险因素研究进展[J].心血管病学进展,2020,(12):1243.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.005]
MA XiuyingJIA Fengpeng.Update about the Risk Factors of Hypertrophic Cardiomyopathy Complicated with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2020,(1):1243.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.005]
[4]邓清文,何森.肥厚型心肌病合并心房颤动的研究进展[J].心血管病学进展,2021,(4):27.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.010]
DENG Qingwen,HE Sen.Hypertrophic Cardiomyopathy Complicated with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2021,(1):27.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.010]
[5]尚依一 刘罗 庞明杰 张艳.基因检测在肥厚型心肌病中的应用进展[J].心血管病学进展,2021,(6):512.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.009]
SHANG Yiyi,LIU Luo,PANG Mingjie,et al.Gene Detection for Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2021,(1):512.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.009]
[6]王娟 杨艳敏.肥厚型心肌病发生缺血性卒中的危险因素和管理策略研究进展[J].心血管病学进展,2021,(7):582.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.002]
WANG Juan,YANG Yanmin.Risk Factors and Management Strategies of Ischemic Stroke in Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2021,(1):582.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.002]
[7]武志刚 孙佳莉 王巍.基于心脏磁共振成像的肥厚型心肌病患者早期峰值充盈率与舒张功能相关性的研究[J].心血管病学进展,2021,(7):658.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.020]
WU Zhigang,SUN Jiali,WANG Wei.Correlation Between Early Peak Filling Rate and Diastolic Function in Patients with Hypertrophic Cardiomyopathy Based on Cardiac Magnetic Resonance Imaging[J].Advances in Cardiovascular Diseases,2021,(1):658.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.020]
[8]蓝庆肃 武锋超 马兰虎 韩冰 徐金 彭瑜 张钲.Mavacamten治疗肥厚型心肌病的研究进展[J].心血管病学进展,2021,(11):1028.[doi:10.16806/j.cnki.issn.1004-3934.2021.11.000]
LAN Qingsu,WU Fengchao,MA Lanhu,et al.Mavacamten in Treatment of Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2021,(1):1028.[doi:10.16806/j.cnki.issn.1004-3934.2021.11.000]
[9]李珂 赵海娟 赵耀 黄松群 郭志福.肥厚型心肌病合并心房颤动的导管消融[J].心血管病学进展,2022,(5):399.[doi:10.16806/j.cnki.issn.1004-3934.2022.05.004]
LI Ke,ZHAO Haijuan,ZHAO Yao,et al.Catheter Ablation of Hypertrophic Cardiomyopathy with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2022,(1):399.[doi:10.16806/j.cnki.issn.1004-3934.2022.05.004]
[10]王蕊 赵鹏军.儿童肥厚型心肌病诊断方法及其对猝死风险评估的价值[J].心血管病学进展,2023,(8):681.[doi:10.16806/j.cnki.issn.1004-3934.2023.08.003]
WANG Rui,ZHAO Pengjun.Diagnostic Methods of Hypertrophic Cardiomyopathy in Children and Its Value in Risk Assessment of Sudden Death[J].Advances in Cardiovascular Diseases,2023,(1):681.[doi:10.16806/j.cnki.issn.1004-3934.2023.08.003]